Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stem Cell Therapy for Parkinson's Disease: A Mechanistically Distinct Role for Muse Cells.

Journal of clinical medicine·2026
Same author

Single-Institution Analysis of Immediate and Delayed Jaw Reconstruction.

Journal of reconstructive microsurgery·2026
Same author

Stem cells enhance mitochondrial function in experimental Huntington's disease.

Stem cells (Dayton, Ohio)·2026
Same author

Isolation of SSEA-3-Positive Muse Cells in Canine and Feline Adipose Tissues.

Stem cells and development·2026
Same author

Perioperative Blood Pressure Kinetics and Hematoma Rates in Head and Neck Free Flaps.

Journal of reconstructive microsurgery·2026
Same author

A transcriptional program associated with neurotransmission in the living human brain.

Molecular psychiatry·2026

Related Experiment Video

Updated: Nov 3, 2025

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

19.9K

Cell-based treatment for perinatal hypoxic-ischemic encephalopathy.

You Jeong Park1, Cesario V Borlongan1, Mari Dezawa2

  • 1Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.

Brain Circulation
|June 4, 2021
PubMed
Summary

Cell-based therapies show promise for treating neonatal hypoxic-ischemic encephalopathy (HIE). Stem cell treatments may reduce inflammation and aid brain repair, with ongoing trials exploring efficacy and safety.

Keywords:
Cell therapycerebral palsyhypoxic-ischemic encephalopathyinflammationregenerative medicinestem cells

More Related Videos

The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
08:47

The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia

Published on: November 19, 2008

36.0K
Early Pathological and Magnetic Resonance Detection of Cerebral Injury Using a Rat Model of Neonatal Hypoxic Ischemic Encephalopathy
05:52

Early Pathological and Magnetic Resonance Detection of Cerebral Injury Using a Rat Model of Neonatal Hypoxic Ischemic Encephalopathy

Published on: October 28, 2022

883

Related Experiment Videos

Last Updated: Nov 3, 2025

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

19.9K
The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia
08:47

The Hypoxic Ischemic Encephalopathy Model of Perinatal Ischemia

Published on: November 19, 2008

36.0K
Early Pathological and Magnetic Resonance Detection of Cerebral Injury Using a Rat Model of Neonatal Hypoxic Ischemic Encephalopathy
05:52

Early Pathological and Magnetic Resonance Detection of Cerebral Injury Using a Rat Model of Neonatal Hypoxic Ischemic Encephalopathy

Published on: October 28, 2022

883

Area of Science:

  • Neuroscience
  • Regenerative Medicine
  • Neonatal Research

Background:

  • Hypoxic-ischemic encephalopathy (HIE) is a leading cause of neonatal brain injury with limited treatment options.
  • Current treatment, hypothermia, is only effective within 6 hours for full-term infants.
  • Cell-based therapies offer a promising avenue for HIE treatment, targeting neonatal brain injury.

Purpose of the Study:

  • To review cell sources used in clinical trials for HIE.
  • To evaluate the therapeutic mechanisms of cell-based HIE treatments.
  • To assess the potential of stem cells in managing neonatal neurological complications.

Main Methods:

  • Systematic review of preclinical and clinical studies on HIE cell-based therapies.
  • Searches conducted in PubMed, Web of Science, and ClinicalTrials.gov databases.
  • Analysis of therapeutic effects and underlying mechanisms of various stem cell types.

Main Results:

  • Umbilical cord blood cells, placenta-derived stem cells, and mesenchymal stem cells (MSCs) show promising results in HIE trials.
  • Therapeutic effects are largely attributed to the bystander effect, reducing inflammation and promoting neurogenesis.
  • Multilineage-differentiating stress-enduring (Muse) cells, a subset of MSCs, demonstrate potential in replacing damaged cells and have advanced to clinical trials.

Conclusions:

  • Cell-based therapies, particularly MSCs and Muse cells, hold significant potential for treating HIE.
  • Further research and multi-center trials are crucial to optimize protocols and confirm the safety and efficacy of these treatments.
  • Stem cell transplantation offers a novel strategy to mitigate long-term neurological deficits following neonatal hypoxic-ischemic injury.